Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy

Mayako Uchida, Hiroaki Ikesue, Koji Kato, Kimiko Ichinose, Hiromi Hiraiwa, Asako Sakurai, Katsuto Takenaka, Hiromi Iwasaki, Toshihiro Miyamoto, Takanori Teshima, Nobuaki Egashira, Koichi Akashi, Ryozo Oishi

研究成果: ジャーナルへの寄稿記事

9 引用 (Scopus)

抄録

Purpose. Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy were evaluated. Methods. All data were retrospectively collected from the Kyushu University Hospital's electronic medical record system. Patients age 20 years or older with hematologic malignancies who received multiday chemotherapy were included in the study. All patients received 3 mg of granisetron i.v. 30 minutes before chemotherapy administration. Patients in the aprepitant group received 125 mg of aprepitant orally 60-90 minutes before administration of the first moderately to highly emetogenic chemotherapy (day 1). On day 2 or thereafter, an 80-mg oral dose of aprepitant was administered in the morning for up to five days. The primary endpoint was the percentage of patients who achieved complete response (CR). Results. A total of 42 patients were treated with aprepitant and granisetron as antiemetic prophylaxis between April and December 2010 (aprepitant group), and 40 patients were treated with only granisetron between March 1, 2009, and March 31, 2010, before the introduction of aprepitant. The percentage of patients who achieved CR in the aprepitant group was significantly higher than that in the control group (p = 0.01). Factors that were significantly associated with non-CR included the prophylactic use of aprepitant and chemotherapies containing ≥4 g/m2/day of cytarabine. The rates of adverse drug events (ADEs) did not significantly differ between groups. Conclusion. The addition of aprepitant to granisetron increased the antiemetic effect without influencing ADEs in patients treated with moderately to highly emetogenic multiday chemotherapy for hematologic malignancies.

元の言語英語
ページ(範囲)343-349
ページ数7
ジャーナルAmerican Journal of Health-System Pharmacy
70
発行部数4
DOI
出版物ステータス出版済み - 2 15 2013

Fingerprint

aprepitant
Antiemetics
Hematologic Neoplasms
Safety
Drug Therapy
Granisetron
Drug-Related Side Effects and Adverse Reactions
Electronic Health Records
Cytarabine

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Health Policy

これを引用

Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy. / Uchida, Mayako; Ikesue, Hiroaki; Kato, Koji; Ichinose, Kimiko; Hiraiwa, Hiromi; Sakurai, Asako; Takenaka, Katsuto; Iwasaki, Hiromi; Miyamoto, Toshihiro; Teshima, Takanori; Egashira, Nobuaki; Akashi, Koichi; Oishi, Ryozo.

:: American Journal of Health-System Pharmacy, 巻 70, 番号 4, 15.02.2013, p. 343-349.

研究成果: ジャーナルへの寄稿記事

Uchida, Mayako ; Ikesue, Hiroaki ; Kato, Koji ; Ichinose, Kimiko ; Hiraiwa, Hiromi ; Sakurai, Asako ; Takenaka, Katsuto ; Iwasaki, Hiromi ; Miyamoto, Toshihiro ; Teshima, Takanori ; Egashira, Nobuaki ; Akashi, Koichi ; Oishi, Ryozo. / Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy. :: American Journal of Health-System Pharmacy. 2013 ; 巻 70, 番号 4. pp. 343-349.
@article{d501980c5bdd44d69f28b5c462e04783,
title = "Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy",
abstract = "Purpose. Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy were evaluated. Methods. All data were retrospectively collected from the Kyushu University Hospital's electronic medical record system. Patients age 20 years or older with hematologic malignancies who received multiday chemotherapy were included in the study. All patients received 3 mg of granisetron i.v. 30 minutes before chemotherapy administration. Patients in the aprepitant group received 125 mg of aprepitant orally 60-90 minutes before administration of the first moderately to highly emetogenic chemotherapy (day 1). On day 2 or thereafter, an 80-mg oral dose of aprepitant was administered in the morning for up to five days. The primary endpoint was the percentage of patients who achieved complete response (CR). Results. A total of 42 patients were treated with aprepitant and granisetron as antiemetic prophylaxis between April and December 2010 (aprepitant group), and 40 patients were treated with only granisetron between March 1, 2009, and March 31, 2010, before the introduction of aprepitant. The percentage of patients who achieved CR in the aprepitant group was significantly higher than that in the control group (p = 0.01). Factors that were significantly associated with non-CR included the prophylactic use of aprepitant and chemotherapies containing ≥4 g/m2/day of cytarabine. The rates of adverse drug events (ADEs) did not significantly differ between groups. Conclusion. The addition of aprepitant to granisetron increased the antiemetic effect without influencing ADEs in patients treated with moderately to highly emetogenic multiday chemotherapy for hematologic malignancies.",
author = "Mayako Uchida and Hiroaki Ikesue and Koji Kato and Kimiko Ichinose and Hiromi Hiraiwa and Asako Sakurai and Katsuto Takenaka and Hiromi Iwasaki and Toshihiro Miyamoto and Takanori Teshima and Nobuaki Egashira and Koichi Akashi and Ryozo Oishi",
year = "2013",
month = "2",
day = "15",
doi = "10.2146/ajhp120363",
language = "English",
volume = "70",
pages = "343--349",
journal = "American Journal of Health-System Pharmacy",
issn = "1079-2082",
publisher = "American Society of Health-Systems Pharmacy",
number = "4",

}

TY - JOUR

T1 - Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy

AU - Uchida, Mayako

AU - Ikesue, Hiroaki

AU - Kato, Koji

AU - Ichinose, Kimiko

AU - Hiraiwa, Hiromi

AU - Sakurai, Asako

AU - Takenaka, Katsuto

AU - Iwasaki, Hiromi

AU - Miyamoto, Toshihiro

AU - Teshima, Takanori

AU - Egashira, Nobuaki

AU - Akashi, Koichi

AU - Oishi, Ryozo

PY - 2013/2/15

Y1 - 2013/2/15

N2 - Purpose. Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy were evaluated. Methods. All data were retrospectively collected from the Kyushu University Hospital's electronic medical record system. Patients age 20 years or older with hematologic malignancies who received multiday chemotherapy were included in the study. All patients received 3 mg of granisetron i.v. 30 minutes before chemotherapy administration. Patients in the aprepitant group received 125 mg of aprepitant orally 60-90 minutes before administration of the first moderately to highly emetogenic chemotherapy (day 1). On day 2 or thereafter, an 80-mg oral dose of aprepitant was administered in the morning for up to five days. The primary endpoint was the percentage of patients who achieved complete response (CR). Results. A total of 42 patients were treated with aprepitant and granisetron as antiemetic prophylaxis between April and December 2010 (aprepitant group), and 40 patients were treated with only granisetron between March 1, 2009, and March 31, 2010, before the introduction of aprepitant. The percentage of patients who achieved CR in the aprepitant group was significantly higher than that in the control group (p = 0.01). Factors that were significantly associated with non-CR included the prophylactic use of aprepitant and chemotherapies containing ≥4 g/m2/day of cytarabine. The rates of adverse drug events (ADEs) did not significantly differ between groups. Conclusion. The addition of aprepitant to granisetron increased the antiemetic effect without influencing ADEs in patients treated with moderately to highly emetogenic multiday chemotherapy for hematologic malignancies.

AB - Purpose. Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy were evaluated. Methods. All data were retrospectively collected from the Kyushu University Hospital's electronic medical record system. Patients age 20 years or older with hematologic malignancies who received multiday chemotherapy were included in the study. All patients received 3 mg of granisetron i.v. 30 minutes before chemotherapy administration. Patients in the aprepitant group received 125 mg of aprepitant orally 60-90 minutes before administration of the first moderately to highly emetogenic chemotherapy (day 1). On day 2 or thereafter, an 80-mg oral dose of aprepitant was administered in the morning for up to five days. The primary endpoint was the percentage of patients who achieved complete response (CR). Results. A total of 42 patients were treated with aprepitant and granisetron as antiemetic prophylaxis between April and December 2010 (aprepitant group), and 40 patients were treated with only granisetron between March 1, 2009, and March 31, 2010, before the introduction of aprepitant. The percentage of patients who achieved CR in the aprepitant group was significantly higher than that in the control group (p = 0.01). Factors that were significantly associated with non-CR included the prophylactic use of aprepitant and chemotherapies containing ≥4 g/m2/day of cytarabine. The rates of adverse drug events (ADEs) did not significantly differ between groups. Conclusion. The addition of aprepitant to granisetron increased the antiemetic effect without influencing ADEs in patients treated with moderately to highly emetogenic multiday chemotherapy for hematologic malignancies.

UR - http://www.scopus.com/inward/record.url?scp=84874041940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874041940&partnerID=8YFLogxK

U2 - 10.2146/ajhp120363

DO - 10.2146/ajhp120363

M3 - Article

C2 - 23370141

AN - SCOPUS:84874041940

VL - 70

SP - 343

EP - 349

JO - American Journal of Health-System Pharmacy

JF - American Journal of Health-System Pharmacy

SN - 1079-2082

IS - 4

ER -